Table 1.
Model | Medication | Baseline rhythm | Result | Reference |
---|---|---|---|---|
Normal mouse cardiomyocytes | Apamin | Paced rhythm | Little effect | Xu et al., 2003 |
Normal human cardiomyocytes | Apamin | Paced rhythm | No effect | Nagy et al., 2009 |
Rabbit HF | Apamin | Sinus rhythm | Prolonged APD and prevents acute APD shortening, Anti-arrhythmic: Prevent spontaneous VF | Chua et al., 2011 |
Human HF cardiomyocytes | Apamin | Paced rhythm | Prolonged APD | Chang et al., 2013 |
Rabbit HF | Apamin | Sinus rhythm | Prolonged APD Anti-arrhythmic: Reduced APD heterogeneity |
Hsieh et al., 2013 |
Rabbit HF | Apamin | AV block | Prolonged APD Pro-arrhythmic: Increased EADs and TdP |
Chang et al., 2013b |
Rabbit Chronic MI | Apamin | Sinus rhythm | Prolonged APD and prevents acute APD shortening | Lee et al., 2013 |
Rat Acute MI | Apamin, UCL1684 | Sinus rhythm | Anti-arrhythmic: APD prolongation | Gui et al., 2013 |
Canine HF cardiomyocytes; Human HF cardiomyocytes | Apamin | Paced rhythm | Prolonged APD Pro-arrhythmic: Increased EADs |
Bonilla et al., 2014 |
APD, action potential duration; AV, atrioventricular; EAD, early afterdepolarization; HF, heart failure; MI, myocardial infarction; TdP, torsades de pointes; VF, ventricular fibrillation.